Guided design for the development of an evolution-proof influenza vaccine DOI Creative Commons

Lauren Myburgh,

Karlijn van Loon, Elisabeth J. M. Huijbers

и другие.

Vaccine, Год журнала: 2025, Номер 59, С. 127281 - 127281

Опубликована: Май 20, 2025

Influenza remains a significant public health concern, particularly among high-risk populations, due to its capacity cause annual epidemics and potentially trigger global pandemics. Despite the availability of countermeasures such as vaccines antiviral treatments, their effectiveness is hindered by factors resistance development with manufacturing influenza vaccine still heavily relying on decades-old technologies. This review therefore examines mechanisms which viruses evade host immunity evaluates current emerging approaches enhance vaccine-mediated protection. Advances targeting conserved hemagglutinin (HA) stem, incorporating multiple HA subtypes, use adjuvants are discussed, alongside increased attention neuraminidase (NA) other viral components immunogenic targets. Strategic epitope prediction, through glycan masking, evolutionary forecasting, consensus sequence design, offer promising frameworks for rational design. Furthermore, delivery platforms, including recombinant protein, mRNA, conjugate explored potential elicit broad durable immunity. Collectively, these developments highlight multifaceted approach towards design effective interventions against this persistent healthcare challenge.

Язык: Английский

Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine DOI Creative Commons

Lauren Myburgh,

Haiko Karsjens,

Athanasios Blanas

и другие.

Vaccine, Год журнала: 2025, Номер 54, С. 126989 - 126989

Опубликована: Март 14, 2025

The spike glycoprotein is a key factor in the infection cycle of SARS-CoV-2, as it mediates both receptor recognition and membrane fusion by virus. Therefore, this study, we aimed to design multi-peptide conjugate vaccine against targeting early stages virus's life cycle. We used iBoost technology, which designed induce immune responses low- or non-immunogenic epitopes. selected six peptide sequences, each representing domain protein (i.e., binding (RBM), subdomain 1 (SD1), 2 (SD2), S1/S2, S2' sequences (FP + S2'), heptad repeat (HR1)). Immunization studies mice displayed targeted humoral cellular specific peptides simultaneously, while inducing cross-protection Delta Omicron coronavirus variants. Moreover, vaccinated hamsters challenged with SARS-CoV-2 elicited high antibody levels peptides, induced neutralizing resulted less weight loss compared controls. This highlights potential for improving viral control disease outcomes when utilizing strategy. using technology conjunction our strategy, were able successfully target non-immunodominant regions activating arms adaptive system.

Язык: Английский

Процитировано

1
Multiplex genetic manipulations in Clostridium butyricum and Clostridium sporogenes to secrete recombinant antigen proteins for oral-spore vaccination DOI Creative Commons
Yanchao Zhang, Tom S. Bailey, Philip Hittmeyer

и другие.

Microbial Cell Factories, Год журнала: 2024, Номер 23(1)

Опубликована: Апрель 24, 2024

Abstract Background Clostridium spp. has demonstrated therapeutic potential in cancer treatment through intravenous or intratumoral administration. This approach expanded to include non-pathogenic clostridia for the of various diseases, underscoring innovative concept oral-spore vaccination using clostridia. Recent advancements field synthetic biology have significantly enhanced development -based bio-therapeutics. These are particularly notable areas efficient protein overexpression and secretion, which crucial feasibility oral strategies. Here, we present two examples genetically engineered candidates: one as an vaccine other antiviral against SARS-CoV-2. Results Using five validated promoters a signal peptide derived from sporogenes , series full-length NY-ESO-1/CTAG1, promising candidate, expression vectors were constructed transformed into C. butyricum . Western blotting analysis confirmed secretion NY-ESO-1 clostridia, with specific leading detection signals. Additionally, fusion reported bacterial adjuvant improved immune recognition led cloning difficulties E. coli The use AUU start codon successfully mitigated toxicity issues enabling recombinant proteins We further demonstrate successful replacement PyrE loci high-expression cassettes carrying adjuvant-fused NY-ESO-1, achieving plasmid-free capable secreting antigens. Lastly, study extends its multiplex genetic manipulations engineer SARS-CoV-2-related Spike_S1 Conclusions that can produce antigen (NY-ESO-1 antigens) manipulations, utilizing codon. overcomes challenges difficult findings underscore harnessing commensal emphasizing applicability non-canonical translation initiation across diverse species broad implications medical industrial biotechnology.

Язык: Английский

Процитировано

4
Rerouting therapeutic peptides and unlocking their potential against SARS-CoV2 DOI

Namrata Prashar,

Sameer Khairullah MOHAMMED,

Raja Natesan Sella

и другие.

3 Biotech, Год журнала: 2025, Номер 15(5)

Опубликована: Апрель 4, 2025

Язык: Английский

Процитировано

0
Guided design for the development of an evolution-proof influenza vaccine DOI Creative Commons

Lauren Myburgh,

Karlijn van Loon, Elisabeth J. M. Huijbers

и другие.

Vaccine, Год журнала: 2025, Номер 59, С. 127281 - 127281

Опубликована: Май 20, 2025

Influenza remains a significant public health concern, particularly among high-risk populations, due to its capacity cause annual epidemics and potentially trigger global pandemics. Despite the availability of countermeasures such as vaccines antiviral treatments, their effectiveness is hindered by factors resistance development with manufacturing influenza vaccine still heavily relying on decades-old technologies. This review therefore examines mechanisms which viruses evade host immunity evaluates current emerging approaches enhance vaccine-mediated protection. Advances targeting conserved hemagglutinin (HA) stem, incorporating multiple HA subtypes, use adjuvants are discussed, alongside increased attention neuraminidase (NA) other viral components immunogenic targets. Strategic epitope prediction, through glycan masking, evolutionary forecasting, consensus sequence design, offer promising frameworks for rational design. Furthermore, delivery platforms, including recombinant protein, mRNA, conjugate explored potential elicit broad durable immunity. Collectively, these developments highlight multifaceted approach towards design effective interventions against this persistent healthcare challenge.

Язык: Английский

Процитировано

0